This study tests a new medicine called casdatifan for people with advanced cancers and kidney cancer, called clear cell renal cell carcinoma (ccRCC). In the first part of the study, researchers want to see if casdatifan is safe when taken alone. Later, they will see how it works by itself or with other medicines like cabozantinib or zimberelimab.

To join, participants must have a cancer that can’t be treated with existing options and meet certain health criteria, like a creatinine clearance of at least 40 mL/min, to ensure their kidneys are working well. Participants should not have had major surgery recently or used specific vaccines or treatments.

• Study Length: Time varies as there are different parts to the study.
• Visit Requirements: Regular visits are needed to monitor health and collect data.
• Risks: Potential risks include side effects from the medicines or complications if existing health issues are present.